DENTSPLY SIRONA Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
DENTSPLY SIRONA reported Q2 2026 net sales of $898M (down 4.1% YoY from $936M), GAAP diluted EPS of $0.18 (vs. loss of $0.22 in Q2 2025), and adjusted EPS of $0.52 (flat vs. prior year). The company expanded its Medline Sinclair partnership for Connected Technology Solutions in Canada, repurchased 1.3M shares (~$12M), and maintained 2026 guidance: net sales $3.5–$3.6B and adjusted EPS $1.40–$1.50. Adjusted EBITDA margin held steady at 21.3%. Operating cash flow improved to $99M (vs. $48M in Q2 2025), aided by ~$44M in tariff refunds.
Why this rating
Q2 results in-line with expectations; modest top-line decline offset by margin stability. Guidance reiteration and distributor partnership expansion show execution, but no material event relative to $3.2B market cap. Routine quarterly disclosure.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.